Travel grant 2024 Switzerland, Swiss Nordic Bio 2024 on March 7
| Reference number | |
| Coordinator | Iscaff Pharma AB |
| Funding from Vinnova | SEK 12 329 |
| Project duration | March 2024 - March 2024 |
| Status | Completed |
| Venture | Global cooperation 2024 |
Important results from the project
Through pitch presentation and direct scheduled meetings, identify and meet possible partners for Iscaffpharma and its development of a platform for evaluation of new cancer drugs as well as new targets for the development of cancer drugs.
Expected long term effects
Interactions through 1-1 meetings and follow-up discussions are the main means of reaching new R&D collaborations and investors to enable continued R&D and entrances for commercial agreements and partnerships. At these meetings, several investors and partners met, which are then followed up through email contacts and digital meetings.
Approach and implementation
VD Per Setterberg, Iscaffpharma, attended the meeting on March 7th with meeting bookings, discussions and booking follow-up meetings with partners and investors. Listen to panel discussions about funding, partnership and development of the life science industry. 1) Network with organizations and companies 2) Pitch presentation Iscaffpharma and its development of a platform for evaluation of new cancer drugs as well as new targets for the development of cancer drugs. 3) Partnership discussions in the form of 1 to 1 meetings